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The thymus plays a major role in myasthenia gravis (MG). Our recent ﬁnding of a persistent Epstein-Barr (EBV) virus infection
in some MG thymuses, combined with data showing that the thymus is in a proinﬂammatory state in most patients, supports a
viral contribution to the pathogenesis of MG. Aim of this study was to gain further evidence for intrathymic chronic inﬂammation
and EBV infection in MG patients. Transcriptional proﬁling by low density array and real-time PCR showed overexpression of
genes involved in inﬂammatory and immune response in MG thymuses. Real-time PCR for EBV genome, latent (EBER1, EBNA1,
LMP1) and lytic (BZLF1) transcripts, and immunohistochemistry for LMP1 and BZLF1 proteins conﬁrmed an active intrathymic
EBVinfection,furthersupportingthehypothesis thatEBVmight contribute to onset or perpetuation of the autoimmune response
in MG. Altogether, our results support a role of inﬂammation and EBV infection as pathogenic features of MG thymus.
1.Introduction
Myasthenia gravis (MG) is a well-characterized autoimmune
disorder of the neuromuscular junction. In most cases
(>80%), the disease is associated with the production of
autoantibodies against the acetylcholine receptor (AChR),
which impair neuromuscular transmission resulting in mus-
cle weakness and disabling fatigability. Less frequently, MG is
associated with the presence of antibodies against the muscle
speciﬁc kinase (MuSK) receptor [1]. The remaining MG
patients—referred as seronegative—are negative for anti-
AChR and anti-MuSK antibodies, although a proportion of
them (66%) has recently been found to have low-aﬃnity
anti-AChR antibodies [2].
A wealth of data supports the involvement of thymus
in the pathogenesis of MG with AChR autoantibodies.
Marked pathological alterations of thymus occur in over
80% of AChR-positive patients [1], comprising thymic
hyperplasia observed in 50–60% of AChR-positive cases and
variable proportion of seronegative cases [3–5], and thy-
moma present in 10–15% of cases. Thymus with hyperplasia
contains B-cell inﬁltrates that can organize into ectopic
germinal centers (GCs) forming B-cell follicles (follicular
hyperplasia) or be distributed throughout thymic medulla
(diﬀuse hyperplasia, also called thymitis) [3]. Ten to 20% of
AChR-positive cases have an atrophic thymus very similar to
that of age-matched controls with regard to the amount of
adipose tissue and epithelial space and characterized by the2 Autoimmune Diseases
presence of inﬁltrating B cells, in some cases forming GCs
in the residual islands of medullary parenchyma [3, 4, 6],
indicative of thymic hyperplasia and immune activation.
The thymus of AChR-positive MG patients contains all
the components required to initiate and sustain the autoim-
mune response: the autoantigen, expressed on muscle-like
myoid cells [7] and thymic epithelial cells (TECs) [8], pro-
fessional antigen-presenting cells [9], AChR-speciﬁc T cells
[10], and plasma cells producing anti-AChR antibodies
[11]. As sign of thymic involvement in MG pathogenesis,
thymectomy results in stable remission in a high proportion
of AChR-positive patients (see [12] and references included).
Both genetic and environmental factors are involved in
the etiology of MG. Viral infections are the prime environ-
mental factors suspected to play a role in the development
of autoimmunity through mechanisms which include gen-
eral activation of the host immune system and molecular
mimicry [13]. In the former process, pathogens act as
promoters of autosensitization mainly by initiating an innate
immune response that in turn stimulates inﬂammation and
activates the host immune system [13]. Striking evidence of
chronic inﬂammation of thymus in most MG patients [14,
15] makes plausible the hypothesis that persistent viruses
or other microbial agents may contribute to intrathymic
etiologic mechanisms of the disease. Our recent ﬁndings
provided indication of a viral contribution to onset or main-
tenance of the intrathymic autoimmune response in MG
patients [6, 16]. In a study, we found evidence of a chronic
poliovirus infection in the thymus of some (14.7%) MG
patients, suggesting that persisting viruses, which stimulate
innate immune responses and chronic inﬂammation, might
be responsible for immunological alterations and autosensi-
tization in the thymus [16]. In another study, we identiﬁed
an abnormal accumulation of Epstein-Barr virus- (EBV-)
infected B cells and plasma cells in MG thymuses but not in
normal control thymuses [6]. We found viral DNA and both
viral latency and lytic gene mRNAs and proteins in most of
the examined MG thymuses, indicating EBV persistence and
reactivation [6]. Since EBV has the unique ability to disrupt
B-cell regulatory checkpoints and to interfere with the B-cell
diﬀerentiation program [17, 18], our ﬁnding suggested that
EBV infection may contribute to chronic B-cell activation
and persistent autoimmune response in this organ in MG
patients [6].
Herein, we searched for new evidence of inﬂammation
and EBV infection in MG thymus. Our objectives were (a)
to characterize MG thymus for the expression of genes
involved in biological processes related to immune response,
including genes encoding for proinﬂammatory molecules,
regulators of immune response, and antiviral agents; (b) to
gain further evidence of EBV infection in MG thymus by
extending the search for EBV presence from the 17MG thy-
muses examined in our previous study [6] to an additional
19MG thymuses.
2.MaterialandMethods
2.1. MG Patients, Thymic Tissues, and Control Cell Lines. The
studyincludedpathologicalthymusesfromMGpatientswho
underwent thymectomy as therapeutic treatment and non-
pathological thymuses obtained during heart surgery in
babies and adult cardiopathic subjects. Written informed
consent was obtained from all patients for thymectomy and
useofthymusforresearchpurposes.Thestudywasapproved
by the Ethics Committee of the Carlo Besta Neurological
Institute.
Thymic tissues from 10 AChR-positive MG patients
(Patient Group 1), including 3 with follicular hyperplasia,
3 with thymitis, and 4 with thymic involution (see Table 1
for clinical features), were individually used for TaqMan
Low-Density Array (LDA) Immune Panel analysis. Two non-
pathological thymuses from babies aged 0.5 and 10 months
were used as reference tissues in the LDA analysis. Real-
time RT-PCR, performed to conﬁrm LDA data, was carried
out on MG thymuses from the 10 patients included in
the LDA and from additional 17 patients (Patient Group
2, Table 1), including 6 with follicular hyperplasia, 6 with
thymitis, and 5 with thymic involution, previously resulted
positive for intrathymic EBV infection [6]; as control, the 2
nonpathologicalthymusesexaminedbyLDAsandadditional
5EBV-negativenonpathological thymuses(meanage:31.4 ±
17.3) [6] were analyzed.
Real-time PCR for EBV DNA and RNA detection was
carriedoutonthymusesfrom19MGpatients(P atientGroup
3, Table 1), including 15 AChR-positive MG patients (6
with follicular hyperplasia, 4 with thymitis, and 5 with
thymic involution) and 4 seronegative MG patients (3 with
follicular hyperplasia and 1 with thymitis). Thymuses from 2
adult healthy subjects, previously resulted EBV-negative [6],
were analyzed to test the speciﬁcity of the PCR procedures
described in what follows.
For each thymus, some fragments were ﬁxed in 10%
formalin for histopathological classiﬁcation; other fragments
were snap-frozen and stored at −80◦C. EBV-positive lym-
phoblastoid JY and EBV-negative human Jurkat T-cell lines
were cultured at 37◦Ci n5 %C O 2 in RPMI 1640 (Euroclone,
Pero, Italy) with 10% foetal bovine serum (Invitrogen,
Carlsbad, CA), 2mM sodium pyruvate (Invitrogen), 2mM
L-glutamine, and 100U penicillin/streptomycin (all from
Euroclone) and used as controls in molecular analyses and
immunohistochemistry.
2.2. Transcriptional Proﬁling
2.2.1. RNA Isolation and cDNA Synthesis. Total RNA was
extracted by 20–50mg of frozen thymic fragments using
the TRIzol method (Invitrogen) and treated with DNase I
(Ambion Applied Biosystems, Foster City, CA). Random-
primed cDNA was prepared using Superscript II reverse
transcriptase (Invitrogen) following the manufacturer’s
instructions. As a control of retrotranscription eﬃciency, β-
actin gene was ampliﬁed in the same samples.
2.2.2. TaqMan Low-Density Array (LDA). cDNAs prepared
from 10MG thymuses (Patient Group 1) and 2 control
thymuses were analysed by TaqMan Low-Density Immune
Proﬁling Array, product number 4342510 (Applied Biosys-
tems), a microﬂuidic card containing predesigned primerAutoimmune Diseases 3
Table 1: Clinical features of MG patients included in the study.
Patient Group 1 Hyperplasia (n = 3) Thymitis (n = 3) Involuted (n = 4)
Sex (F/M) 3/02 /12 /2
Age at disease onset (years) mean ± SD 23.3 ±9.33 0 .9 ±3.72 9 .1 ±16.3
Age at surgery (years) mean ± SD 26.3 ±11.03 2 .0 ±3.63 1 .5 ±15.2
Ab AChR-positive 2 3 4
Seronegative 1 0 0
Immunosuppressive therapy 2 2 4
Patient Group 2 Hyperplasia (n = 6) Thymitis (n = 6) Involuted (n = 5)
Sex (F/M) 5/1 5/1 4/1
Age at disease onset (years)a mean ± SD 23.6 ±7.22 3 .4 ±12.63 0 .0 ±10.2
Age at surgery (years) mean ± SD 25.5 ±6.02 5 .2 ±11.93 3 .0 ±11.2
Ab AChR-positive 6 4b 4
Seronegative 0 1 1
Immunosuppressive therapy 5c 45
Patient Group 3 Hyperplasia (n = 9) Thymitis (n = 5) Involuted (n = 5)
Sex (F/M) 8/1 4/1 3/2
Age at disease onset (years)d mean ± SD 26.4 ±9.23 1 .0 ±3.83 0 .7 ±14.4
Age at surgery (years) mean ± SD 30.0 ±10.93 3 .4 ±4.03 2 .20 ±11.8
Ab AChR-positive 6 4 5
Seronegative 3 1 0
Immunosuppressive therapy 3 4 5
aAge at disease onset was not available for two patients, one with hyperplasia and one with thymitis. bInformation on autoantibody presence in serum was
not available in one patient. cData on the therapy before thymectomy were missing in one patient. dAge at disease onset was not available for two patients,
one with hyperplasia and one with involuted thymus.
probe sets speciﬁc for 90 genes, implicated in the immune
response (e.g., cytokines/chemokines and their receptors,
transcription factors, stress response, cell surface receptors,
and signal transduction), and for 6 housekeeping genes
(e.g., β-actin and glyceraldehyde 3-phosphate dehydroge-
nase, GAPDH). To run the array, the cDNA was added to the
PCR master mix (Applied Biosystems) and loaded into the
eight sample-loading channels of LDA. Each channel with 48
wells contains primer probe sets for 12 diﬀerent genes tested
in quadruplicate. After a brief centrifugation, the arrays
were run on an upgraded Applied Biosystems 7900HT Real-
Time PCR System (performed at Cogentech, Consortium
for Genomic Technologies c/o IFOM-IEO Campus, Milan,
Italy). GAPDH was used to normalize the results. For
each target gene, relative expression was calculated from
the formula 2−Ct using as calibrators normalized values
obtained from control thymuses.
2.2.3. Real-Time RT-PCR. cDNA samples prepared from
thymic fragments of Patient Group 1 and 2, and 7 control
thymuses, were subjected to real-time PCR for IL-6, IL-
10, IFN-1β,I F N - γ, MxA, and HLA-DRα genes. Predesigned
functionally tested TaqMan gene expression assays (Applied
Biosystems) were used: assay ID Hs00174131 m1 for IL-6;
assay ID Hs00174086 m1 for IL-10; assay ID Hs01077958 s1
for IFN-β; assay ID Hs00174143 m1 for IFN-γ; assay ID
Hs00182073 m1forMxA;assayIDHs00740413 g1forHLA-
DRα. Each cDNA was ampliﬁed in triplicate using 7500
Fast Real-time PCR system (Applied Biosystems) in a PCR
volume of 20μL containing 10μL of TaqMan Fast Universal
PCR Master Mix and 1μL of TaqMan gene expression assays
(all from Applied Biosystems). GAPDH mRNA was analyzed
as endogenous control by using TaqMan Predeveloped
Assay Reagents Human GAPDH (Applied Biosystems). The
omission of cDNA was taken as no template control. Data
analysis followed the same method (2−ΔΔCt method) as that
in LDA.
2.2.4. Statistical Analysis. One-way ANOVA with Bonferroni
multiple comparison post hoc test was performed to assess
the signiﬁcance of diﬀerences in transcriptional proﬁling
LDA data. In real-time RT-PCR analysis, Mann-Whitney U
test was used to compare IL-6, IL-10, IFN-β,I F N - γ,M x A ,
andHLA-DRαtranscriptlevelsincontrolandMGthymus.P
values < 0.05 were considered signiﬁcant. GraphPad PRISM
version 4.0 (GraphPad Software, San Diego, CA) was used
for data elaboration and statistical analysis.
2.3. Tissue Processing for EBV Detection
2.3.1. DNA and RNA Isolation. For DNA and RNA isolation
aimed to detect EBV genome and transcripts, snap-frozen
thymic specimens from the donors belonging to the Patient
Group 3 and from 2 control thymuses were used. For
each OCT-included snap-frozen thymus, a total of 18 serial
sections were obtained using a cryostat (Leica Microsystems,
Nußloch, Germany) for alternate DNA, RNA isolation, or
immunohistochemistry. 30-μm sections 1, 4, 7, 10, 13, and4 Autoimmune Diseases
16 were collected for DNA extraction, 30-μms e c t i o n s3 ,6 ,9 ,
12, 15, and 18 for RNA extraction, and 6-μms e c t i o n s2 ,5 ,8 ,
11, 14, and 17 for immunohistochemistry.
For DNA isolation, thymic sections were resuspended in
300μg/mL proteinase K in digestion buﬀer, homogenized
with TissueLyser LT (Qiagen, Valencia, CA), and incubated
at 50◦C overnight; DNA was extracted following the stan-
dard phenol-chloroform protocol. RNA was isolated from
thymic sections by using the TRIzol method (Invitrogen),
after homogenization with TissueLyser LT (Qiagen). RNA
integrity was checked on ethidium bromide containing 1%
agarose gel in Tris-borate/EDTA buﬀer. All RNA samples
were treated with DNase I (Ambion Applied Biosystems).
ConcentrationofDNAandRNAwasestimatedbyNanodrop
2000c Spectrophotometer (Thermo Fisher Scientiﬁc, Wilm-
ington, DE).
2.3.2. Real-Time PCR for EBV DNA. Real-time PCR speciﬁc
for the BamHI-W repeated multiple splices [19]w a sp e r -
formed on each DNA sample. Genomic DNA (0.8μg) was
ampliﬁed in a ﬁnal volume of 25μL containing 12.5μLo f
TaqMan Universal PCR Master Mix (Applied Biosystems),
900nM each primer, and 175nM probe. Primers and probe
used were as in [19]. Following two steps at 50◦Cf o r2m i n
and 95◦C for 10min, 50 cycles of 1sec at 95◦C and 1min
at 60◦C were carried out by a 7500 Fast Real-time PCR
System (Applied Biosystems). Real-time PCR reactions were
performed in duplicate, including a no template control
consisting in the omission of DNA. A threshold cycle (Ct)
value was calculated by determining the point at which
the ﬂuorescence exceeded a threshold limit (10 times the
standard deviation of the baseline). Samples were deﬁned
positive for Ct values lower than 38 cycles. DNA integrity
and ampliﬁcation eﬃciency was checked by amplifying a
fragment of the β-globin gene from each DNA preparation.
To test sensitivity and eﬃciency of the real-time PCR
assay, dilution series (0.5 to 5 × 103 copies of EBV genome)
of the DNA isolated from the EBV-positive JY cells [20]w e r e
analyzedintriplicate.Thestandardcurvewasobtainedauto-
matically by using the 7500 Fast System software. As negative
control, DNA derived from Jurkat cells was ampliﬁed.
2.3.3. Real-Time RT-PCR for EBV Latency Transcripts. Real-
time RT-PCR for the detection of EBV-encoded small RNA
(EBER) 1, EBV nuclear antigen (EBNA) 1, and latent
membrane protein (LMP) 1 transcripts was performed on
DNase-treated RNA (0.5μg) from thymic sections. TaqMan
PCR primers and probes for EBER1, EBNA1, and LMP1
were as in [19, 21]. EBNA1 and LMP1 primers and probes
were incorporated into TaqMan Gene Expression Assays by
Applied Biosystems. RNA was ampliﬁed in a ﬁnal volume
of 20μL containing 5μL of 4x TaqMan Fast Virus 1-Step
Master Mix and 1μL of TaqMan Gene Expression Assay for
EBNA1, LMP1, and GAPDH or 1.25μMe a c hp r i m e ra n d
0.18μM probe for EBER1 (all from Applied Biosystems).
TaqMan Fast Virus 1-Step Master Mix (Applied Biosystems)
is designed for high-sensitivity virus detection and performs
reverse transcription and PCR all in one reaction.
Real-time RT-PCR reactions were incubated on 7500
Fast Real-Time PCR System (Applied Biosystems) at 50◦C
for 5min and 95◦C for 15, followed by 50 cycles at 95◦C
for 15 sec and 60◦C for 1min. Real-time RT-PCR reactions
wereperformedinduplicate,includinganotemplatecontrol
consisting in the omission of RNA. Detection of GAPDH
transcript (Applied Biosystems) served as control for the
presence of template RNA and eﬃciency of real-time RT-
PCR.Athresholdcycle(Ct)valuewascalculatedasdescribed
aboveforEBVDNAdetection.Samplesweredeﬁnedpositive
for Ct value lower than 38 cycles.
To test sensitivity and eﬃciency of the real-time RT-PCR
assays, dilution series (from 0.1 to 105 cells per reaction)
of the RNA obtained from the EBV-positive cell line JY
were ampliﬁed in presence and absence of 1μgo fR N A
from the EBV-negative Jurkat T-cell line. The standard curve
was obtained automatically by using the 7500 Fast System
software. As negative control, RNA derived from Jurkat T
cells was ampliﬁed. Each point of standard curve was run in
triplicate. PCR product identity was checked by sequencing
on an ABI 3100 Genetic Analyzer (Applied Biosystems).
2.3.4. Real-Time RT-PCR for BZLF1 Lytic EBV Transcript.
For the detection of EBV lytic transcript BZLF1, DNase-
treated RNA obtained from thymic sections was retrotran-
scribed into random-primed cDNA by using SuperScript
Vilo cDNA Synthesis kit (Invitrogen). cDNA corresponding
to 500ng of RNA was ampliﬁed with the BZLF1-out forward
and reverse primers previously reported [22]. Ampliﬁcation
was performed in a ﬁnal volume of 50μL consisting of 1x
PCR buﬀer (Finnzyme, Espoo, Finland), 0.2mM dNTPs
(Applied Biosystems), 0.4μMo fe a c hp r i m e r ,a n d1 Uo f
DNAZyme (Finnzyme). After a predenaturation step at 95◦C
for 5min, 40 cycles were repeated at 95◦Cfor1minand59 ◦C
for 1min followed by an extension step of 7min at 72◦C. For
eachsample,5μLofPCRproductweresubjectedtoreal-time
PCR in a volume of 20μL containing 10μLo fPower SYBR
Green PCR Master Mix (Applied Biosystems) and 0.8μM
each of BZLF1-inn primers [22] and incubated on 7500
Real-time PCR System (Applied Biosystems). As a control of
retrotranscription eﬃciency, β-actin gene was ampliﬁed in
the same samples. cDNA from JY and Jurkat cell lines was
ampliﬁed as positive and negative control, respectively, and
PCR product identity was checked by sequencing on an ABI
3100 Genetic Analyzer (Applied Biosystems).
2.3.5. Immunohistochemistry. Immunohistochemistry was
performedon6-μm sections from snap frozen thymic tissues
belonging to Patient Group 3 (n = 19). All the 19 thymuses
were immunostained with antibodies speciﬁc for human
CD20 (1:300; clone L26, Dako, Glostrup, Denmark) and
CD138 (1:50; clone MI15, Dako). Sections from 8MG thy-
muses (4 follicular hyperplasia, 2 thymitis, and 2 involuted
thymuses) were immunostained with antibodies for latent
EBV protein LMP-1 (ready-to-use, clone CS 1-4, isotype
IgG1, Dako) and lytic EBV protein BZLF1 (1:10; isotype
IgG2, Lifespan Biosciences Inc., Seattle, WA). Sections were
ﬁxed with 4% paraformaldehyde and incubated for 10minAutoimmune Diseases 5
in 1.5% hydrogen peroxide in methanol, to eliminate
endogenous peroxidase activity. For BZLF1 immunostain-
ing, sections were treated with 0.1%Triton X 100 for 10min.
To block nonspeciﬁc binding, sections were incubated for 1
hour in 5% BSA. Incubations with primary antibodies were
performed overnight at 4◦C. Sections were then incubated
withDakoCytomationEnVision+SystemLabelledPolymer-
HRP Anti-Mouse (Dako) for 1 hour. Peroxidase reaction was
visualized with 3,3  diaminobenzidine (DAB) plus substrate
buﬀer (Dako). All sections were counterstained with hema-
toxylin, visualized by optical microscopy (Nikon, Germany),
and examined using Image Proplus (Media Cybernetics,
Silver Spring, MD). Immunohistochemistry speciﬁcity was
controlled by omitting the primary antibodies or replacing
them with isotype-speciﬁc nonimmune IgG (Dako).
3. Results
3.1. Transcriptional Proﬁling of MG Thymus. To characterize
the thymic transcriptome of MG patients for the expression
of genes implicated in inﬂammation and immune response,
we preliminarily used LDA approach on a small series of
MG patients and found that gene expression proﬁle of
MG thymuses were distinct from that of control thymuses,
delineating a thymic condition characterized by chronic
inﬂammation and active immune response, as previously
reported [14, 15]. Starting from our LDA results and from
the published data [14, 15], we selected six genes (IL-6,
IFN-γ, HLA-DRα, IL-10, IFN-β,a n dM x A ) ,e x p e c t e dt ob e
dysregulated during inﬂammation and immune response,
and analysed their expression by real-time RT-PCR on a
higher number of MGand controlthymuses, including EBV-
positive MG thymuses and EBV-negative nonpathological
thymuses [6]. The results conﬁrmed inﬂammatory state and
immune response activation in MG thymus. LDA and real-
time RT-PCR results are described in detail in what follows.
3.1.1. LDA Data Reﬂect Inﬂammatory State and Immune Ac-
tivation in MG Thymus. The ninety genes included in the
LDA assays were successfully ampliﬁed in MG and control
thymuses. The analysis of variance identiﬁed 21 genes whose
expression was signiﬁcantly diﬀerent among the MG and
control sample groups (P<0.05). The other genes were
expressed at similar level in all groups except some of them
(e.g., Bcl-2-like protein 1, a potent inhibitor of cell death;
angiotensin II type-2 receptor, a protein belonging to the G-
protein coupled receptor 1 family involved in programmed
cell death; CD38, a transmembrane glycoprotein involved
in cell adhesion, signal transduction, and calcium sig-
nalling) whose expression levels were lower in MG thymuses
compared to controls, although the diﬀerences were not
statistically signiﬁcant. In Table 2, we reported LDA data for
genes that were signiﬁcantly upregulated in at least one of
the three MG thymus subgroups versus normal thymuses.
MG thymuses with thymitis showed the highest number
of upregulated genes, prevalently cytokines and chemokines
(Table 2). Among cytokines, IL-6—a well-known highly
inﬂammatory cytokine implicated in chronic inﬂammatory
and autoimmune diseases [23]—was the most overexpressed
gene in each MG thymus subgroup compared to normal
thymus, followed by IL-1β, a proinﬂammatory cytokine
mainly produced by myeloid cells and also involved in vari-
ous inﬂammatory and autoimmune diseases [24]( Table 2).
Transcriptional levels of other molecules able to modulate
inﬂammatory process, including colony-stimulating factor
(CSF) 1, IL-7, IL-10, IL-12p35, TNF-α,a n dI F N - γ,w e r e
also higher in MG thymic conditions with respect to control
thymuses (Table 2). A signiﬁcant overexpression of IL-10—
a Th2-produced cytokine having inhibitory properties on
Th1 function and promoting humoral immune response
[25, 26]—was identiﬁed whatever MG thymic subgroup was
considered (Table 2).
Among chemokines, the chemokine receptor CXCR3,
involved in recruitment and maintenance of activated T cells
in the inﬂammatory site [27], was signiﬁcantly upregulated
in follicular hyperplasia and thymitis (Table 2), according
to previous data [28]. Transcriptional levels of RANTES
(CCL5),IL-8,monocytechemoattractantprotein-(MCP-)1,
macrophages inﬂammatory protein- (MIP-) 1α—monocyte
chemotactic factors that are highly produced during micro-
bial infection [29]—were increased in each thymic MG
subgroup (Table 2).
We found that mRNA level of vascular endothelial
growth factor A (VEGF-A)—a growth factor mediating vas-
cular permeability and vasculogenesis [30]—was signiﬁ-
cantly upregulated in thymitis compared with normal thy-
muses (Table 2).
Moreover, LDA identiﬁed upregulation in MG thymus
of some genes involved in immune response and antigen
presentation. As expected, we observed increased expression
of CD19—marker of B cells—in each MG thymus subgroup
(Table 2), reﬂecting B cell inﬁltration characteristic of MG
thymus [3, 6]. Transcriptional level of CD152 (CTLA-4)
was higher in MG than normal thymuses, especially in
thymitis. CD152 is a surface molecule mostly considered as
a negative regulator of T-cell activation [31]; recently, it has
been demonstrated that CD152 signalling may play a role in
antimicrobial infection by endowing eﬀe c t o rTc e l l sw i t ht h e
capacitytomigratetositesofinﬂammationandlymphnodes
[32].
In line with previous data [15], we found that MG thy-
muses had high expression levels of HLA-DRα (Table 2)a n d
complement component C3 mRNA levels.
Among the 21 upregulated genes in MG thymus,
there were also two genes, the SMAD family member 7
(SMAD7)—a nuclear regulator of transforming growth fac-
tor-β whose expression is altered in inﬂammatory diseases
[33]—and the endothelial converting enzyme 1 (ECE)—a
metalloprotease involved in proteolytic processing of endo-
thelial precursors [34].
Diﬀerences between hyperplasia, thymitis, and involuted
thymus were signiﬁcant for CSF1, RANTES, VEGF-A,
CXCR3, CD19, CD86, HLA-DRα, and MADH7 mRNAs,
which were signiﬁcantly higher in thymitis than involuted
thymus; IL-1β and MCP-1 mRNAs, which were signiﬁ-
cantly higher in thymitis than hyperplasia; IL-7, IL-12p35,
TNF-α,I F N - γ, IL-8, and CD34 mRNAs, which were6 Autoimmune Diseases
Table 2: Upregulated genes in follicular hyperplasia, thymitis, and involuted thymus versus normal thymus identiﬁed by TaqMan low-
density arrays (LDAs).
Gene symbol Biological function Fold changesa
Hyperplasia Thymitis Involuted
CSF1 Cytokine 3.61 (1.23) 7.16 (2.78)∗ 2.22 (1.15)
IL-1β Cytokine 11.29 (13.44) 51.72 (30.57)∗ 10.92 (10.92)
IL-6 Cytokine 29.56 (14.44) 1621.00 (513.70)∗∗ 72.60 (20.25)∗∗
IL-10 Cytokine 5.93 (0.41)∗ 7.64 (1.12)∗ 7.14 (0.61)∗∗
IL-12p35 Cytokine 4.09 (3.47) 15.42 (6.55)∗ 3.42 (2.11)
TNF-α Cytokine 2.97 (1.61) 8.92 (2.95)∗ 3.27 (1.10)
IFN-γ Cytokine 2.21 (0.78) 15.24 (4.89)∗ 1.78 (2.30)
RANTES Cytokine 4.90 (1.07)∗ 6.79 (1.26)∗ 3.31 (0.95)
IL-7 Growth factor 5.25 (2.27) 21.18 (8.36)∗ 2.78 (0.92)
VEGF-A Growth factor 5.01 (2.57) 20.07 (9.74)∗ 4.62 (3.02)
IL-8 Chemokine 3.90 (3.25) 16.22 (5.61)∗ 3.57 (2.00)
CXCR3 Chemokine receptor 4.56 (0.50)∗ 6.15 (1.19)∗ 2.57 (0.70)
MCP-1 Chemokine 4.41 (1.36) 31.08 (5.68)∗ 20.53 (1.60)∗∗
MIP-1α Chemokine 17.93 (11.38) 35.01 (11.34)∗ 16.11 (7.89)
CD19 CD antigen 4.37 (0.17)∗ 6.91 (1.41)∗ 3.51 (1.25)
CD86 CD antigen 1.82 (0.09) 3.82 (1.52)∗ 1.05 (0.44)
CD152 CD antigen 3.38 (0.49) 7.87 (3.37)∗ 2.97 (1.77)
HLA-DRα MHC Class II 2.12 (0.39) 4.15 (1.05)∗ 1.58 (0.78)
C3 Complement component 10.66 (4.75) 29.12 (6.87)∗ 12.83 (10.88)
SMAD7 Cell signaling 2.53 (0.87) 4.78 (0.62)∗∗ 1.61 (1.06)
ECE1 Metalloprotease 2.57 (0.97) 6.34 (2.51)∗ 2.42 (1.51)
aFor each gene, mean fold change (±SD) for the diﬀerent MG thymus subgroups compared to normal thymuses is given. Fold change was calculated from the
formula 2−Ct; ∗P < 0.05, ∗∗P < 0.01 (Bonferroni test). The genes in bold were further analysed by real-time RT-PCR.
signiﬁcantly higher in thymitis than hyperplasia and invo-
luted thymus.
3.1.2. Real-Time RT-PCR Shows Upregulation of Genes
Involved in Inﬂammation and Antiviral Response in MG
Thymus. Data derived from LDA were validated on a higher
number of patients (Patient Group 2) and controls by
conventional real-time PCR. We selected IL-6, IFN-γ,a n d
HLA-DRα genes, known to be upregulated during inﬂam-
matory response against microbial infection and resulted
upregulated in MG thymus by LDA (Patient Group 1,
erefTabletab1). We also investigated the expression of IL-
10, for its role in modulating B cell function and humoral
responses [26], type I IFN-β, which plays a pivotal role in
the host immune response against viral infections [25], and
MxA, an important mediator of type I IFNs [35].
We found a signiﬁcant upregulation of IL-6 in each
MG thymus subgroup compared with normal thymuses
(Figure 1(a)), conﬁrming LDA data. An increased expres-
sion of IL-10 was also observed in all MG thymuses; in
particular, IL-10 expression was signiﬁcantly increased in
hyperplasiaandthymitiscases(Figure 1(b)).Transcriptional
level of IFN-β was signiﬁcantly higher in thymitis and
involuted thymuses (Figure 1(c)), whereas IFN-γ transcript
was signiﬁcantly up-regulated in hyperplasia and thymitis
cases (Figure 1(d)). A signiﬁcant increase in MxA expression
was detected in each MG thymic subgroup, supporting the
hypothesis of an ongoing antiviral response in MG thymus
(Figure 1(e)). HLA-DRα also showed a signiﬁcant upregu-
lation in each MG thymic pathology, again supporting the
inﬂammatory state of MG thymus (Figure 1(f)).
3.2. Characterization of MG Thymus for the Presence of EBV
DNA, RNA, and Proteins. To conﬁrm previous evidence of
EBV infection in MG thymus [6], we investigated thymic
t i s s u e sf r o m1 9M Gp a t i e n t s( P a t i e n tG r o u p3 ,Table 1)a n d
two adult healthy donors for the presence of EBV DNA
(BamHI-W repeat region), RNA (EBER1, EBNA1, LMP1,
and BZLF1), and proteins (LMP1 and BZLF1).
3.2.1. Presence of Inﬁltrating B Cells and Plasma Cells in
MG and Control Thymuses. MG thymuses were initially
examined for the presence of lymphoid B cell inﬁltrates and
plasma cells, in order to verify that the thymic fragments
under investigation contained B cells/plasma cells potentially
positive to EBV. Presence of lymphoid B cell inﬁltrates
(diﬀuse or organized in GCs) and plasma cells was found in
all MG thymus specimens examined (Figures 2(a) to 2(f));
thus, alternate sections collected from these specimens were
used for further analysis of EBV DNA and RNA presence.
3.2.2. Detection of EBV DNA. We used real-time PCR to
detect EBV genome (BamHI-W repeat region) in MG
thymuses. We ﬁrst validated our real-time PCR assay byAutoimmune Diseases 7
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Figure 1: Relative expression of IL-6 (a), IL-10 (b), IFN-β (c), IFN-γ (d), MxA (e), and HLA-DRα (f) in the thymus of MG patients. The
transcripts were analysed by real-time PCR analysis starting from total RNA extracted from the thymus of MG patients with hyperplasia
(n = 9), thymitis (n = 9), and thymic involution (n = 9), and 7 healthy subjects. Relative expression of the 6 genes was normalized to
GAPDH and calculated as 2−ΔΔCt; normalized values for nonpathological thymuses were used as calibrator. Values shown are means ± SEM
of duplicate determinations. P values were obtained by the Mann-Whitney U test.8 Autoimmune Diseases
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Figure 2: Presence of B cell lymphoid inﬁltrates and plasma cells in MG and control thymuses analysed for EBV detection. (a, b) Thymus
withfollicularhyperplasia(MG1).CD20+Bcellsaggregatetoformagerminalcenter(GC)inthethymicmedulla(a).ManyCD138+plasma
cells are present at the periphery of a GC (b).(c, d) Thymus with thymitis (MG11).Many CD20+ B cells (c) and CD138+ plasma cells (d) are
sparse throughout the medullary inﬁltrates. (e, f) Involuted thymus (MG17). The residual thymic parenchyma contains lymphoid inﬁltrates
with numerous CD20+ B cells (e) and CD138+ plasma cells (f). (g, h) Normal thymus from an adult healthy subject. Some CD20+ cells (g)
and rare CD138+ plasma cells (h) are present in the thymic parenchyma. Magniﬁcations: ×1 0( a ,b ,e ,f) ;×20 (c, d); ×40 (g, h).
demonstrating that it was able to detect EBV DNA with
high sensitivity and speciﬁcity. By amplifying dilution series
of DNA from the EBV-positive JY cells [20], we obtained a
standard curve showing linearity in the range from 0.5 to
5 × 103 copies per reaction, with 0.99 regression coeﬃcient
(R2)a n d−3.56 slope, corresponding to 90.98% eﬃciency.
We argued that the molecular system resulted in high and
constant ampliﬁcation eﬃciency and that >0.5 copy ofAutoimmune Diseases 9
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Figure 3: Real-time PCR for EBV genome detection (BamHI-W repeats). (a) Dilution series of DNA (ranging from 0.5 to 105 copies of
EBV genome per reaction), extracted from the JY lymphoblastoid cell lines, were analysed as described in Section 2. Real-time PCR resulted
in high and constant ampliﬁcation eﬃciency for >0.5 copies of EBV genome per reaction. (b) Genomic EBV W repeats were detectable in
6/9 hyperplastic thymuses, 2/5 thymitis, and 4/5 involuted thymuses, but not in two nonpathological control thymuses. Real-time PCR was
performed for 50 cycles, and results are expressed as 50-Ct.
Table 3: Detection of EBV DNA and RNA transcripts in MG thymus by real-time PCR.
Patient Thymic pathology Anti-AChR antibodiesa EBV DNAb Latent markersb Lytic markerb
EBER1 EBNA1 LMP1 BZLF1
MG1 Hyperplasia Positive + + + − +
MG2 Hyperplasia Positive + + + + +
MG3 Hyperplasia Positive − ++ −−
MG4 Hyperplasia Positive − ++ − +
MG5 Hyperplasia Positive + + + + +
MG6 Hyperplasia Positive + + + + +
MG7 Hyperplasia SN + −−++
MG8 Hyperplasia SN −− + − +
MG9 Hyperplasia SN + + + − +
MG10 Thymitis Positive −− − ++
MG11 Thymitis Positive − ++ − +
MG12 Thymitis Positive + −−− −
MG13 Thymitis Positive + + + −−
MG14 Thymitis SN −− ++ +
MG15 Involuted Positive + + −− +
MG16 Involuted Positive + + + + +
MG17 Involuted Positive + + + + +
MG18 Involuted Positive + + + + +
MG19 Involuted Positive − ++ − +
Ctr1c Normal SN −− − − −
Ctr2c Normal SN −− − − −
aSN: seronegative (AChR- and MuSK-negative) patients. bEBV genome and transcripts were analysed by real-time PCR techniques as described in Section 2.
Results are expressed as follows: + detected (Ct value <38); − not detected (Ct value >38). cCtr: nonpathological control thymus.
genome for reaction could be quantiﬁed with an acceptable
level of accuracy (Figure 3(a)). β-globin control gene was
detected at similar level in all MG and control samples (data
not shown). EBV genome was detected in 12/19 (63.2%) MG
thymuses (6/9 hyperplasia, 2/5 thymitis, and 4/5 involuted
thymuses) but not in control thymuses (Figure 3(b) and
Table 3) and EBV-negative Jurkat T-cell line.
3.2.3. Detection of Latent EBV Transcripts. We used real-
time RT-PCR to analyse latent EBER1, EBNA1, and LMP1
transcripts in MG and control thymuses. We ﬁrst validated
our real-time RT-PCR assays by performing a number of
controlexperiments.ByusingRNAfromtheEBV-positiveJY
cells, we demonstrated that our assays were able to detect the
target transcripts in RNA from one EBV-positive JY cell for10 Autoimmune Diseases
reaction (Figures 4(a) to 4(c)) but not in the EBV-negative
Jurkat T-cell line. Standard curves for the detection of the
three targets showed R2 always higher than 0.99 and slope
ranged from −3.22 and −3.47, corresponding to eﬃciencies
higher than 94%. Real-time RT-PCR were also able to detect
the target RNA from one EBV-positive JY cell in the presence
of 1μg of RNA from the EBV-negative Jurkat T-cell line
(∼100,000cells),indicatingthatourmolecularsystemscould
detect 1 positive cell/∼100,000 negative cells.
EBER1 (Figure 4(d)), EBNA1 (Figure 4(e)), and LMP1
(Figure 4(f)) transcripts were detected in 14/19, 15/19,
and 9/19 MG thymuses, respectively, but not in control
thymuses (Figures 4(d) to 4(f) and Table 3). Housekeeping
gene GAPDH was detected in all the specimens analysed
(Figure 4(g)).
3.2.4. Detection of Lytic BZLF1 EBV Transcript. BZLF1 tran-
script was detected in 16/19MG thymuses but not in normal
c o n t r o lt h ym u s e s( Figure 5(a)). In all MG and control cDNA
specimens, the housekeeping gene β-actin was eﬃciently
ampliﬁed (Figure 5(b)).
3.2.5. Detection of Latent LMP1 and Lytic BZLF1 EBV Pro-
teins. To conﬁrm results of molecular analysis at protein
level, we performed immunohistochemistry assays to detect
LMP1 and BZLF1 proteins, markers of EBV latency and
reactivation, respectively, on 8MG and 2 control thymuses.
Cells expressing LMP1 were detected in 7/8MG thymuses
analysed but not in normal thymuses (Figure 6 and Table 4).
Immunoreactivity for LMP1 was mainly detected in GC and
perifollicular areas in hyperplasia (Figures 6(e) and 6(f))
and within medullary inﬁltrates in thymitis and involuted
thymuses (Figures 6(g) and 6(h)). We found cells expressing
the early lytic phase EBV protein BZLF1 in thymic medulla
of most MG thymuses examined (7/8) but not in normal
thymuses (Figures 6(l) to 6(p) and Table 4), thus suggesting
productive, not only latent, EBV infection in the thymus of
MG patients.
4. Discussion
This study conﬁrms and extends previous evidence of in-
ﬂammationandviralinfectioninthethymusofMGpatients.
4.1. Inﬂammation and Active Immune Response Characterize
the Thymus of MG Patients. Previous analyses of the genes
characterizing the hyperplastic thymus using microarray
and real-time PCR approaches showed that transcripts of
a large number of genes associated with inﬂammation
and immune response were signiﬁcantly upregulated in
hyperplastic MG thymuses compared to controls [14, 15].
The upregulated genes included IFN-regulated genes, MHC
Class II molecules, Ig family, and B cell-related genes, whose
increase reﬂected an inﬂammatory state and a generalized B
cell inﬁltration in hyperplastic MG thymus [14, 15].
In the present study, we used LDA approach to charac-
terize the thymic transcriptome in 10MG patients (Patient
Group 1) whose thymuses had histopathological features of
Table 4: Detection of EBV latent LMP1 and lytic BZLF1 proteins in
MG thymus by immunohistochemistry.
Patient Thymic Anti-AChR EBV proteinsb
pathology antibodiesa LMP1 BZLF1
MG1 Hyperplasia Positive + +
MG5 Hyperplasia Positive + +
MG6 Hyperplasia Positive + +
MG9 Hyperplasia SN + +
MG11 Thymitis Positive − +
MG13 Thymitis Positive + −
MG16 Involuted Positive + +
MG17 Involuted Positive + +
Ctr1c Normal SN −−
Ctr2c Normal SN −−
aSN: seronegative (AChR- and MuSK-negative) patients. bResults of im-
munostaining for LMP1 and BZLF1 are expressed as follows: + presence
of positive cells; − absence of positive cells. cCtr: nonpathological control
thymus.
hyperplasia, thymitis, and thymic involution, and in non-
MG subjects having normal thymuses.
LDA, a TaqMan quantitative PCR based on microﬂuidic
systems, represents a valuable approach for sensitive and
quantitative gene expression proﬁling that enables high
throughput screening in functional genomics by simul-
taneously analysing mRNA expression of multiple genes
in human tissues [36]. LDA technology allowed us to
analyse mRNA of 90 genes belonging to diﬀerent biological
categories, including genes involved in inﬂammatory and
immune responses. All the target transcripts were detected
in MG and control thymuses. However, 21 genes were
upregulatedinMGthymusescomparedtocontrols(Table 2):
(a)proinﬂammatory cytokines, able to activate immune cells
and having antiviral properties (i.e., IL-6, IL-1β,C S F ,I L -
7, IL12p35, TNF-α,a n dI F N - γ); (b) cytokines, chemokines,
and molecules involved in migration, homing, and survival
of lymphocytes in biological site of inﬂammation or infec-
tion (i.e., IL-6, RANTES, IL-8, MCP-1, MIP-1α,C X C R 3 ,
and CD152); (c) B-cell-related genes and genes related or
potentially related to antigen presentation and humoral
response (i.e., IL-10, HLA-DRα, CD19, and complement
component C3).
The expression of proinﬂammatory cytokines reached
the highest values in the thymitis cases (Table 2). Most of
thesecytokinesareknowntoworkinsynergyandtopromote
inﬂammation and immune response during host defence,
especially against viral infections [25]. Some of them are
potent inﬂammatory molecules mainly involved in acute
inﬂammation (i.e., IL-6, IL-1β,T N F - α, and CSF); others
are mainly involved in establishing chronic inﬂammation
and promoting humoral and cellular immune response (i.e.,
IL-7, IL-10, IL-12, and IFN-γ)[ 25]. Upregulation of IL-6
and the chemokine RANTES in MG compared to normal
thymus was in line with previous studies showing that
these genes were abnormally overexpressed in MG TECs
either at basal condition [37] or (IL-6) when stimulatedAutoimmune Diseases 11
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Figure 4: Real-time RT-PCR for the detection of latent EBER1, EBNA1, and LMP1 transcripts. (a, b, c) Analysis of sensitivity of the assay
for EBER1 (a), EBNA1 (b), and LMP1 (c) showed that the three EBV latent transcripts could be detected in RNA extracted from a single JY
EBV-infected cell. (d, e, f, g) EBER1 (d), EBNA1 (e), and LMP1 (f) were detected in most of the examined MG thymuses but not in normal
control thymuses. All MG and control thymuses analysed showed high signals for endogenous control GAPDH ampliﬁcation (g). Real-time
RT-PCR was performed for 50 cycles, and results are expressed as 50-Ct.
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Figure 5: Real-time RT-PCR for the detection of lytic BZLF1 transcript. (a) Real-time RT-PCR for BZLF1 could detect the lytic transcript in
7/9 hyperplastic thymuses, 3/5 thymitis, and 5/5 involuted thymuses, but not in normal control thymuses. (b) All MG and control thymuses
analysed showed high signals for endogenous control β-actin ampliﬁcation.12 Autoimmune Diseases
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Figure6:ImmunohistochemistryforlatentLMP1(a)–(h)andlyticBZLF1(i)–(p)EBVproteins.(a)to(h)LMP1immunostaining.Nosignal
of immunoreactivity was observed in negative control performed by incubating sections with isotype-speciﬁc nonimmune IgG (Dako) (a).
LMP1wasnotdetectedinEBV-negativeJurkatT-cellline(b)butwasreadilydetectableinEBV-positiveJYcells(c).Normalthymusesshowed
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CD20+ B cells organized in germinal centers (GCs) ((e) and inset in (e)) or were diﬀused throughout the highly inﬁltrated medullary
region (f). Numerous LMP1+ cells were identiﬁed in thymitis cases (MG13 is shown), that were diﬀused in thymic medulla and frequently
located around Hassall’s corpuscles (HCs), where often concentrate B cells (g). In involuted thymuses (MG16 is shown), numerous LMP1+
cells were scattered in the residual thymic parenchyma and frequently located in thymic inﬁltrated areas around HCs (h). Inset in (e) shows
CD20immunostainingofthesameareaofthemainpanelinaserialsection.Insetsin(f),(g),and(h)showareasofthemainpanelsathigher
power of magniﬁcation to reveal membrane localization of LMP1. (i) to (p) BZLF1 immunostaining. No signal of immunoreactivity was
observed in negative control performed by incubating sections with isotype-speciﬁc nonimmune IgG (Dako) (i). BZLF1 was not detected
in EBV-negative Jurkat T-cell line (j) but was readily detectable in EBV-positive JY cells (k). Normal thymuses showed no immunoreactivity
for BZLF1 antibody (l). In hyperplasia (MG1 is shown), BZLF1+ cells were often detected at the edge of GCs ((m) and inset in (m)) or were
scattered in thymic medulla (n). Inset in (m) shows CD20 immunostaining of the same area of the main panel in a serial section. In thymitis
(MG11 is shown) (o) and involuted thymuses (MG17 is shown) (p), BZLF1+ cells were present in thymic medulla, in some cases located
within medullary inﬁltrates in proximity to HCs. Magniﬁcations: ×2 0( a ,d ,i ,l ) ;×4 0( b ,c ,e ,f ,g ,h ,j ,k ,m ,o ,p ) ;×80 (n).Autoimmune Diseases 13
by lipopolysaccharide (LPS) [38], a major activator of
Toll-like receptor (TLR) 4 known to be upregulated in
MG thymus [39]. IL-6 is a well-known proinﬂammatory
agent with pathological regulatory function on growth and
diﬀerentiation of T- and B-cells [40]; RANTES has been
observed to regulate the transepithelial migration of T cells
[41]. Thus, overexpression of IL-6 and RANTES could
support the migration of peripheral lymphocytes to thymus
and their survival there, contributing to the pathological
remodeling of the gland typical of MG [37]. Overexpression
of IL-10 (Table 2) was also of pathogenic relevance, as IL-10
is a B-cell-related cytokine which modulates inﬂammatory
processes and determines the antibody response by inﬂuenc-
ing B cell activation, proliferation, and diﬀerentiation [26].
IL-10 was found to be upregulated in serum of MG patients
after immunoadsorption, indicating that this cytokine might
be linked with the IgG synthesis or resynthesis process in
MG [42]. Moreover, it has been shown that EBV infection
through EBER signalling is able to induce the expression
of IL-10 in B lymphocytes, where this cytokine could act
as autocrine growth factor [43]. Thus, the observed IL-
10 upregulation may be also explained by the previously
observed intrathymic EBV infection in MG thymus [6]a n d
implicated in B cell abnormalities which characterize this
organ in MG patients.
IFN-γ is a type II interferon which exhibits strong anti-
viral properties and ability to enhance MHC Class I and II
expression on nucleated cells [25]. In our LDA data, both
IFN-γ and HLA-DRα were upregulated in MG thymuses
(Table 2), supporting an antiviral reaction and a local proin-
ﬂammatory environment. Increased expression of MHC
Class II molecules was previously observed by Le Panse and
colleagues [15], whose results indicated that overexpression
of these molecules in MG hyperplastic thymus was not
directly related to the increased B cell number but could be
due to the proinﬂammatory state of MG thymus.
Our transcriptome analysis showed also overexpression
of IL-8, MCP-1, and MIP-1α (Table 2); these are inﬂamma-
tory chemokines linked to innate immune responses and
acting as leukocyte chemotactic factors [29]; their expression
was higher in MG thymuses than in controls (Table 2),
suggesting that they could be implicated in abnormal
recruitment of T and B cells. Chemokine receptor CXCR3,
known to drive migration and homing of activated T cells
in inﬂammatory site [27], was particularly upregulated
in hyperplasia and thymitis (Table 2) conﬁrming previous
observationsofincreasedexpressionofCXCR3anditsligand
IFN-γ-inducible protein 10 in the thymus of MG patients
[28].
The idea that thymic microenvironment in MG patients
is favourable to abnormal migration of T cells is further
supported by the observation that the expression of CD152
(CTLA-4) and its CD86 ligand was increased in MG thy-
muses compared to controls (Table 2). The CD152 molecule
is generally considered as a negative regulator of T-cell
activation [31]; however, a recent study showed that CD152
signalling does not simply silence T cells but endows their
capacity to migrate to sites of infection and secondary
lymphoid organs [32], by upregulating the expression of
C C R 7o nTc e l l s[ 32]. Therefore, the high expression level
of CD152 in MG thymus might be due to the enrichment of
CCR7 + CD152 + T cells within the inﬂamed MG thymus
as a consequence of chemokine expressed on specialized
lymphatic vessels, for example, the CCR7 ligand CCL21
[44]. The increase of VEGF-A, a growth factor mediating
vascular permeability and vasculogenesis [30], and ECE,
a metalloprotease implicated in proteolytic processing of
endothelial precursors [34], might be associated with the
abnormal lymphocyte recruitment and the angiogenic pro-
cesses occurring in MG thymus [44].
Our LDA data showed increased expression of CD19,
marker of B cells, in each MG thymus subgroup, thus
reﬂecting the presence of signiﬁcant B cell inﬁltration in MG
thymus; these results are in line with previous microarray
data obtained from Le Panse and colleagues [15].
We also found increased levels of complement com-
ponent C3 mRNA in MG compared to normal thymuses
(Table 2), consistent with previous observation of persistent
complement attack on AChR-expressing thymic epithelial
andmyoidcellsinMGhyperplasticthymus;thisattackmight
be responsible for an increased level of autoantigen presenta-
tion to dendritic cells sustaining autoimmune reaction [45].
To conﬁrm the MG thymic inﬂammatory state suggested
by LDA data, we performed real-time PCR analysis of six
genes,selectedforplayingkeyrolesininﬂammationandhost
defence responses against infections, in a total of 27MG (Pa-
tient Groups 1 and 2) and 7 control thymuses. These genes
were IL-6, IL-10, IFN-γ, and HLA-DRα, previously analysed
byLDA,andIFN-β andMxA.IFN-β waschosentosearchfor
evidence of action of type I IFNs in MG thymus, as this type
of IFNs plays key roles in host immune response against viral
infections and has been widely implicated in autoimmune
conditions [46]; MxA was investigated as it is an important
mediator of type I IFNs in the innate antiviral response [35].
Real-time PCR analysis conﬁrmed upregulation of IL-6,
IL-10, IFN-γ, and HLA-DRα in MG thymuses compared to
controls(Figure 1).Interestingly,IFN-β andMxAgeneswere
also overexpressed in MG thymuses, supporting the hypoth-
esis of an ongoing antiviral and inﬂammatory response in
MG pathological tissues. Overexpression of IFN-γ and IFN-
β was in agreement with previous data [14] showing that
large number of type I and type II IFN-induced genes were
signiﬁcantly upregulated in hyperplastic MG thymuses com-
pared to controls. Previous transcriptional proﬁle analysis
of thymus from untreated and steroid-treated MG patients
showed that the inﬂammatory state was reduced upon
treatment [47]; in particular, the expression of type I IFN-
induced genes, but not of type II IFN-induced genes, was
normalized, suggesting that inﬂammation downmodulation
by steroids occurs through type I IFN-pathways [47]. Our
thymic transcriptome analysis by LDA and real-time PCR
underlines a generalized thymic inﬂammatory state in MG
patients, with increased expression of inﬂammatory genes
being observed even for patients treated with corticosteroid
before thymectomy (Table 2, Patient Group 1 and 2). This
suggests that inﬂammatory condition does not completely
disappear or is maintained after immunosuppressive treat-
ment. However, the number of steroid-untreated patients14 Autoimmune Diseases
we analysed were low (2/10 patients in LDA and 5/27 in
real-time PCR analysis); thus, further studies are needed to
understand whether immunosuppressive treatment is able to
reduce the MG intrathymic proinﬂammatory condition and
establish whether other genes, besides type I IFN-induced
genes [47], undergo normalization.
The overall results of our transcriptional proﬁling con-
ﬁrm that MG thymus is characterized by a chronic in-
ﬂammatory state. Whether this state is the consequence of
viral infection events remains to be clariﬁed. Our previous
study showing increased expression of TLR 4—key member
of innate immunity—in MG thymuses with thymitis and
thymus involution [39], together with the ﬁnding of a
persistent poliovirus infection in the thymus of some MG
patients [16], strongly supports a role of viral infections and
innateimmunesystemactivationastriggereventsforinﬂam-
mation and intrathymic autosensitization in MG.
4.2. EBV Infection Is Commonly Found in MG Thymus. In
o u rp r e v i o u ss t u d y ,w ed e m o n s t r a t e da c t i v eE B Vi n f e c t i o ni n
17/17 nonneoplastic MG thymuses investigated, irrespective
of thymic pathology, whereas no evidence of EBV infection
was found in 6 control thymuses from adult healthy subjects
[6]. Speciﬁcally, in the MG thymuses analyzed, we found
(a) a high frequency of EBV-infected B cells by in situ
hybridization for EBERs and immunohistochemistry for
latent (EBNA2, LMP1, LMP2A) and lytic (BFRF1, BMRF1,
gp350/220, p160) EBV proteins; (b) expression of latent
(EBNA1, LMP2A) and lytic (BZLF1) genes by nested PCR
reactions on cDNA; (c) presence of EBV DNA by real-time
PCR speciﬁc for LMP1 gene [6].
Inthepresentstudy,weaddressedwhetherEBVinfection
is a characteristic feature of MG thymus by extending our
search for EBV-associated nucleic acids and proteins in
additional19MGthymuses(PatientGroup3).Wedecidedto
apply diﬀerent molecular approaches from those previously
used [6], in order to verify whether we were equally able to
detect EBV DNA and RNA in MG thymus (see Section 2).
Consistent with our previous ﬁndings [6], all 19MG thy-
muses investigated showed signs of EBV infection (Table 3).
EBV DNA was detected in 12/19MG thymuses (Figure 3 and
Table 3); EBV latent or lytic transcripts (often both) were
p r ese ntinall,e x c epto ne(MG12),MGth ym uses,whe r easno
sign of infection was found in two nonpathological controls
(Figure 4andTable 3).TheoneMGsample(MG12)negative
for EBV transcripts, but harbouring inﬁltrating B cells by
immunohistochemistry, had detectable EBV DNA genome,
suggesting that the degree of EBV infection in this thymic
specimen could be low (or conﬁned to few cells).
EBV-encoded RNA called EBER1 is expressed at high
levels in EBV-infected cells during latency [17, 18]; most
MG patients were positive to EBER1 (Figure 4), consistent
with results of our previous study in which the use of in
situ hybridization for EBERs allowed us to identify a high
proportion of EBERs-positive cells in most of the examined
MG thymuses irrespective of the thymic pathology [6]. Here,
the application of real-time RT-PCR to detect EBER1, as well
as the use of independent real-time PCR assays to detect EBV
DNA,LMP1,andEBNA1,stronglyconﬁrmevidenceforEBV
latency in MG thymus.
To establish latent infection, EBV uses four diﬀerent
latency gene programs (latency III, II, I, and 0), each
characterizedbyexpressionofasetofviralgenesthatprovide
activation, growth, and survival signals to infected B cells
[17, 18]. In this study, we detected in MG thymuses EBNA1,
w h i c hi se x p r e s s e di na l lE B Vl a t e n c yp r o g r a m s ,a n dL M P 1 ,
which is expressed in latency III (or growth program) and
latency II (or default program). In our previous study [6],
we searched also for LMP2A (both transcript and protein),
whichisexpressedinlatencyIIIandII,andEBNA2(protein),
the ﬁrst latency protein to be synthesized after infection of
na¨ ıve B cells and expressed only in latency III (or growth
program) [17, 18]. We detected LMP2A, whereas EBNA2
was rarely detected, being identiﬁed only in rare cells in few
MG thymuses, likely newly infected cells [6]. These previous
results, together with those presented here, seem to suggest
that EBV mainly uses the latency II to establish a latent
infection in MG thymus.
Of the EBV lytic genes, we analyzed the immediate early
lytic gene BZLF1, which encodes a transactivator protein
regulating expression of early lytic genes [17, 48]. Consistent
with our previous results [6], BZLF1 transcript was detected
in most (16/19) of the examined pathological thymuses
but in none of controls (Table 3 and Figure 4), indicating
productive viral infection in MG thymus that may result
in new infection events and propagation of EBV infection
within MG thymus.
We demonstrated that our real-time PCR analysis could
detect EBV transcripts in RNA extracted from a single JY
EBV-infected cells (Figures 3 and 4). However, we were
unable to detect all the viral transcripts analysed in all
the MG thymuses investigated, although all patients were
positive for at least one transcript. As suggested by Aloisi
and colleagues [49], this may be due to the fact that the
quality of RNA extracted from fragments of bioptic tissue
sample cannot be exactly compared with that of viable,
highly replicating lymphoblastoid cells that contain multiple
copies of EBV genome and display high transcriptional
activity. Moreover, successful detection of EBV nucleic acids
within a highly heterogeneous cell population, which is
af e a t u r eo fah u m a nt i s s u e ,m a yb ed i ﬃcult to achieve
[49].
To conﬁrm at the protein level the results of molecular
analysis, we performed immunostaining for LMP1 and
B Z L F 1 ,al a t e n ta n dal y t i cm a r k e r( Table 4). As in our pre-
vious study [6], we found numerous LMP1-expressing cells
in the thymic medulla of MG thymuses with hyperplasia,
thymitis, and thymic involution, in areas corresponding to
lymphoid inﬁltrates and (in hyperplasia) to GCs (Figure 6).
LMP1 was not detected in the normal thymuses analysed
(Figure 6). In the same tissue, immunohistochemistry also
revealed the presence of cells positive to BZLF1 in each
MG thymic subgroup but in none of the control thymuses
(Figure 6). LMP1 and BZLF1 proteins were not detected in 2
of the 8MG thymuses analysed (LMP1 in MG11 and BZLF1
in MG13), in which the corresponding transcript was also
not detected.Autoimmune Diseases 15
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Figure 7: Proposed model of virus-induced autoimmunity in MG. A “danger signal” (e.g., pathogen infection) stimulates Toll-like receptor-
(TLR-) mediated innate immune responses (a), whose dysregulated or persistent activation leads to the chronic inﬂammation characteristic
ofMGthymus(b).Thechronicallyestablishedthymicinﬂammatorystate(c),characterizedbyoverexpressionofproinﬂammatorycytokines
(e.g.,IL-6,IL-10),typeIandIIIFNs,andT-andB-lymphocyte-attractingchemokines(e.g.,CXCR3,RANTES,CXCL13,CCL21),isessential,
in the context of a genetically predisposing background, for the establishment of mechanisms (d) contributing to T-cell autosensitization,
including presentation or cross-presentation of “self-epitopes” by TECs or myoid cells expressing the autoantigen; upregulation of MHC
genes; activation of antigen-presenting cells (APCs); as well as the constant priming of autoreactive T cells, which in turn promote
autoimmune response by autoreactive B cells (e). B cell attractants CXCL13 and CCL21 recruit circulating B cells to thymus, including those
harboring EBV (a ). EBV infection itself contributes to thymic inﬂammation (b ). EBV reactivation, inﬂuenced by the inﬂammatory state
(c ), results in EBV propagation to uninfected B cells (d ) including AChR-speciﬁc B cells (e ). The chronically established inﬂammation and
EBV infection promote the maintenance within the thymus of the autoimmune response (f), which may be thus perpetuated in periphery
(g).
Most of the examined patients (12/19) underwent im-
munosuppressive therapy before thymectomy (Table 1). Of
the remaining 7 patients, 6 (MG1, MG3, MG5, MG8, MG9,
and MG13) were only treated with acetylcholinesterase in-
hibitors and one (MG4) was untreated. We found evidence
of EBV infection also in the thymus of these 7 patients, thus
suggesting that intrathymic EBV dysregulation is not the
consequence of immunosuppressive therapy. However, we
cannotexcludethatimmunosuppressivedrugscouldamplify
an established intrathymic EBV infection.
In conclusion, the ﬁndings here presented strengthen the
idea that EBV is implicated in the intrathymic pathogenesis
of MG. EBV infection might result in the maintenance of
the autoimmune response in MG thymus by contributing
to chronic B cell activation and promoting survival and
expansion of autoreactive B cell clones. Whether active in-
trathymic EBV infection is a primary event in MG or
the consequence of an underlying intrathymic process that
results in both attraction of circulating EBV-infected cells
and EBV reactivation in MG thymus needs to be clariﬁed.
The high prevalence of EBV infection in the population and
low incidence of MG suggests that other factors (genetic or
environmental, or both) must intervene together with EBV
to cause MG. It is possible that a preexisting inﬂammatory
state might be necessary for colonization of thymus by EBV-
infectedBcellsandsubsequentreactivationofthesecells,and
in turn a chronic EBV infection itself might play a role in
sustainingchronicintrathymicinﬂammationinMGcreating
a vicious circle.
5. Conclusions
Inﬂammation is an important contributor factor in the de-
velopment and progression of autoimmune diseases. The
results of transcriptional proﬁling here presented, by con-
ﬁrming previous data showing inﬂammation and active
immune response in MG thymus, strongly support the16 Autoimmune Diseases
idea that the creation of a local proinﬂammatory state is a
pathogenic feature of thymus in MG patients.
We postulate that a chronically established thymic in-
ﬂammation may be essential, in the context of a genet-
ically predisposing background, for the establishment of
mechanisms contributing to MG autoimmunity including
presentation of “self-epitopes”; upregulation of MHC genes,
of type I IFNs, of proinﬂammatory cytokines, of adhesion,
and of costimulatory molecules on antigen-presenting cells;
as well as the constant priming of autoreactive T cells
[13]( Figure 7). Evidence of persistent viral presence in MG
thymuses, derived from our recent studies [6, 16], suggests
that an initial pathogen infection might be responsible for
the observed inﬂammatory signature and the subsequent
autoantigen sensitization in MG thymus. In particular, our
recent ﬁnding [6], here conﬁrmed and reinforced, of an
active EBV infection in the intrathymic B cell component
in MG patients suggests that EBV infection, together with
inﬂammation, may be a key step in the intrathymic patho-
genesis of MG. Inﬂammation triggered by an endogenous
or exogenous (e.g., microbial infection) danger signal may
drive the colonization of thymus by EBV-harbouring B cells
a n dt h es u b s e q u e n tE B Vr e a c t i v a t i o n( Figure 7). Persistent
EBV infection itself may contribute to maintain a chroni-
cally inﬂamed thymic microenvironment. In the inﬂamed
thymus, EBV may promote disruption of B-cell tolerance
checkpoints and result in expansion of autoreactive B cell
clones (Figure 7). EBV infection thus could explain how the
autoimmune response can be perpetuated in MG thymus,
since EBV is potentially able to immortalize B cells that are
producing AChR antibodies.
By adding new evidence for inﬂammation and EBV
infections as common feature of MG thymus, our ﬁndings
may have relevant therapeutic implications: they reinforce
the rationale for current therapeutic approaches, particularly
anti-inﬂammatory drug use and thymectomy to remove the
site of infection, and also suggest future rationale preventive
and therapeutic measures for MG, such as EBV vaccination
[50] or regulation of the existing EBV infection by the use of
antiviral agents.
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